6533b7d8fe1ef96bd1269a05

RESEARCH PRODUCT

Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.

Roy RemmenChristian RolfoKonstantinos PapadimitriouLúcia FarrachoAna DolcanFrancesco PassigliaPatrick PauwelsTereza OndøichováMarta CastigliaMarcin Ostrowski

subject

Oncologymedicine.medical_specialtyNon-Small-Cell Lung CancerLung NeoplasmsSettore MED/06 - Oncologia MedicaAntineoplastic AgentsTreatment of lung cancerMedical OncologyTyrosine KinaseGefitinibPharmacotherapyDrug TherapyCarcinoma Non-Small-Cell LungInternal medicineCancer; Drug Therapy; Lung Cancer; Medical Oncology; Non-Small-Cell Lung Cancer; Tyrosine KinasemedicineHumansAnaplastic lymphoma kinaseAnaplastic Lymphoma KinaseLung cancerCancerCrizotinibbusiness.industryLung CancerPublic Health Environmental and Occupational HealthReceptor Protein-Tyrosine KinasesCancermedicine.diseaseErbB ReceptorsImmunologyHuman medicineDrug EruptionsErlotinibFamily PracticebusinessSignal Transductionmedicine.drug

description

Abstract: In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.

yearjournalcountryeditionlanguage
2015-01-09
http://www.jabfm.org